1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460
https://www.brainstorm-cell.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Chaim Lebovits | President & Co-CEO | 878.78k | N/A | 1971 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Brainstorm Cell Therapeutics Inc.’s ISS governance QualityScore as of 1 May 2024 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 2; Compensation: 7.